Evercore ISI Downgrades INSP, Adjusts Price Target to $40
Evercore ISI Group has downgraded INSP to a hold rating with a new price target of $40, a 7.41% downside from the current price.
Key Points
- Evercore ISI Group downgraded INSP to a hold rating on June 23, setting a new price target of $40.
- Evercore ISI Group's $40 price target implies 7.41% downside from Inspire Medical Systems, Inc.'s ($INSP) current $43.20 share price.
- Shares of INSP traded at $41.35 on Tuesday, reflecting the recent analyst update.
- Recent institutional moves include Deerfield Management increasing its stake by 79.5% and Vanguard Capital opening a new position.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Evercore ISI Group has adjusted its outlook on INSP, downgrading the stock to a hold rating on June 23, 2026. Analyst Daniel Markowitz set a new price target of $40, signaling a more cautious view compared to previous expectations.
Evercore ISI Group vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in INSP
Several major funds have also adjusted their positions in INSP. Deerfield Management Company significantly increased its holdings by 1,197,366 shares, now holding a total of 2,703,238 shares valued at about $139.4 million, marking a 79.5% increase. Wellington Management Group added 324,863 shares, bringing its total to 2,535,954 shares worth approximately $130.8 million, a 14.7% increase. Vanguard Portfolio Management LLC opened a new position with 1,637,173 shares valued at around $84.4 million. Meanwhile, Morgan Stanley increased its position by 190,872 shares, now holding 1,450,634 shares valued at $74.8 million, a 15.2% increase.
Inspire Medical Systems, Inc. Stock Down 29.7%
Shares of INSP traded near $41.35 on Tuesday. The stock has experienced a range of institutional activity, as reflected in the recent updates from major funds and analysts.
$INSP price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Inspire Medical Systems, Inc.
Recent insider activity at INSP includes several sales by insiders. Chief Product and Innovation Officer John Rondoni sold 2,641 shares on May 15, 2026, at an average price of $43.28, and 700 shares on May 14, 2026, at $43.01. Shawn McCormick sold 696 shares on May 8, 2026, at $45.31 as part of a planned transaction. Georgia Melenikiotou sold 50 shares on May 1, 2026, at $56.70. On the buying side, Gary Lee Ellis and Cynthia Burks each purchased 3,562 shares on April 30, 2026.
Analysts Set New Price Targets
On June 23, 2026, Evercore ISI Group downgraded INSP to a hold rating, setting a price target of $40. Previously, on May 5, 2026, JP Morgan maintained a hold rating with a $54 target, while Piper Sandler downgraded the stock to a hold with a $55 target. Stifel maintained a buy rating with a $65 price target, and RBC Capital kept its hold rating with a $45 target.
Bottom Line
Evercore ISI's recent downgrade and adjusted price target for INSP highlight a more cautious stance on the stock. This change comes amid various institutional adjustments and insider transactions, offering a mixed picture of market sentiment. Investors often track these updates to gauge potential future performance, keeping in mind that analyst ratings and 13F filings are backward-looking and may not reflect current conditions.
Get Inspire Medical Systems, Inc. alerts
New 13F filings, insider trades, and analyst moves on $INSP, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.